Its main active principles are naftoditrones, mainly hypericin and pseudohypericin. Numerous studies attribute to it the ability to cause changes in the levels of neurotransmitters in the brain. It has an inhibitory effect on monoamine oxidase. It also appears to act on serotonin receptors and other transmitters and modulate the expression of certain cytokines.
Its main application is in the treatment of depression, although it is also indicated in: anxiety, night terrors and neurovegetative disorders associated with climacteric.
In mild to moderate depressive states, somatic alterations with symptoms such as agitation, anxiety, irritability, lack of energy and concentration, loss of interest and illusion, stress and other symptoms related to pre-depressive or depressive states.
It has antioxidant properties, cognitive enhancements and memory improvement, neuroprotective effects that could be useful in the treatment of Alzheimer's disease. It is a powerful inhibitor of the reuptake of serotonin, dopamine and noradrenaline.
According to the Commission E it is indicated in:
psychosomatic disorders. moderate and mild depressive disorders. Anxiety. Nervous fatigue. Indications for ESCOP: psychosomatic disorders such as insomnia, anxiety and irritability.
0
